Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
3.290
-0.020 (-0.60%)
At close: Apr 25, 2025, 4:00 PM
3.190
-0.100 (-3.04%)
Pre-market: Apr 28, 2025, 7:21 AM EDT
Ensysce Biosciences Revenue
In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth. Ensysce Biosciences had revenue of $1.30M in the quarter ending December 31, 2024, with 153.12% growth.
Revenue (ttm)
$5.21M
Revenue Growth
+133.58%
P/S Ratio
0.44
Revenue / Employee
$651,254
Employees
8
Market Cap
4.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ENSC News
- 3 days ago - Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds - Accesswire
- 4 days ago - Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why - Benzinga
- 4 days ago - Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds - Accesswire
- 4 days ago - Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder - Accesswire
- 12 days ago - Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study - Accesswire
- 27 days ago - Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 5 weeks ago - Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain - Accesswire
- 6 weeks ago - Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - Accesswire